On 24 August 2018, orphan designation (EU/3/18/2061) was granted by the European Commission to Pharma Gateway AB, Sweden, for autologous glioma tumour cells treated with antisense molecule directed against the insulin-like growth factor type 1 receptor for the treatment of glioma.
autologous glioma tumour cells treated with antisense molecule directed against the insulin-like growth factor type 1 receptor
|Disease / condition||
Treatment of glioma
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;